BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Flavia Fondevila, Carolina Méndez-Blanco, Paula Fernández-Palanca, Javier González-Gallego, José L. Mauriz. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancersExperimental & Molecular Medicine 2019; 51(9): 1 doi: 10.1038/s12276-019-0308-1
2
Jiang Chen, Dan G. Duda. Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigmsEBioMedicine 2020; 52: 102644 doi: 10.1016/j.ebiom.2020.102644
3
Huisi Liu, Sanduo Zheng, Xinfeng Hou, Ximing Liu, Kaixin Du, Xueyuan Lv, Yulu Li, Fang Yang, Wenhui Li, Jianhua Sui. Novel Abs targeting the N‐terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile‐acid‐related side‐effectsCancer Science 2020; 111(5): 1750 doi: 10.1111/cas.14353
4
Meijuan Zheng, Zhigang Tian. Liver-Mediated Adaptive Immune ToleranceFrontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.02525
5
Zuzana Macek Jilkova, Caroline Aspord, Thomas Decaens. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and ChallengesCancers 2019; 11(10): 1554 doi: 10.3390/cancers11101554
6
Jilin Wang, Teddy Yang, Jie Xu. Regulation of Cancer Immune CheckpointsAdvances in Experimental Medicine and Biology 2020; 1248: 619 doi: 10.1007/978-981-15-3266-5_23
7
Hon-Ping Ma, Hang-Lung Chang, Oluwaseun Adebayo Bamodu, Vijesh Kumar Yadav, Ting-Yi Huang, Alexander T. H. Wu, Chi-Tai Yeh, Shin-Han Tsai, Wei-Hwa Lee. Collagen 1A1 (COL1A1) Is a Reliable Biomarker and Putative Therapeutic Target for Hepatocellular Carcinogenesis and MetastasisCancers 2019; 11(6): 786 doi: 10.3390/cancers11060786
8
Ann-Lii Cheng, Chiun Hsu, Stephen L. Chan, Su-Pin Choo, Masatoshi Kudo. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinomaJournal of Hepatology 2020; 72(2): 307 doi: 10.1016/j.jhep.2019.09.025
9
Maria Tampaki, Evangelos Ionas, Emilia Hadziyannis, Melanie Deutsch, Katerina Malagari, John Koskinas. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular CarcinomaCancers 2020; 12(1): 212 doi: 10.3390/cancers12010212
10
Wafaa M. Rashed, Mohamed Ahmed Mohamed Kandeil, Mohamed O. Mahmoud, Sameera Ezzat. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overviewJournal of the Egyptian National Cancer Institute 2020; 32(1) doi: 10.1186/s43046-020-0016-x
11
Masatoshi Kudo. Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular CarcinomaCancers 2020; 12(5): 1089 doi: 10.3390/cancers12051089
12
Aiqing Ma, Rui Zhang. <p>Diosmetin Inhibits Cell Proliferation, Induces Cell Apoptosis and Cell Cycle Arrest in Liver Cancer</p>Cancer Management and Research 2020; : 3537 doi: 10.2147/CMAR.S240064
13
Eishiro Mizukoshi, Shuichi Kaneko. Immune cell therapy for hepatocellular carcinomaJournal of Hematology & Oncology 2019; 12(1) doi: 10.1186/s13045-019-0742-5
14
Rajinikanth siddalingam, Payal Deepak, Sunita Thakur, Sneha Anand, Shweta Jaiswal, Balasubramaniam Jagdish. Gene based nanocarrier delivery for the treatment of hepatocellular carcinomaJournal of Drug Delivery Science and Technology 2020; : 101837 doi: 10.1016/j.jddst.2020.101837
15
Shun-Zhen Zheng, Ping Sun, Jian-Ping Wang, Yong Liu, Wei Gong, Jun Liu. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cellsWorld Journal of Gastroenterology 2019; 25(22): 2752-2762 doi: 10.3748/wjg.v25.i22.2752
16
Hendra Susanto, Chih-Hong Wang, Aulanni’am Aulanni’am, Adeodatus Yuda Handaya. Enhancing early stage of hepatocellular carcinoma: Does correlate to MicroRNA 122 and miR196a interaction?INTERNATIONAL CONFERENCE ON BIOLOGY AND APPLIED SCIENCE (ICOBAS) 2019; 2120: 070021 doi: 10.1063/1.5115738
17
Fat-Moon Suk, Chao-Lien Liu, Ming-Hua Hsu, Yu-Ting Chuang, Jack P. Wang, Yi-Jen Liao. Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinomaScientific Reports 2019; 9(1) doi: 10.1038/s41598-019-53863-2
18
Ziyu Liu, Yan Lin, Jinyan Zhang, Yumei Zhang, Yongqiang Li, Zhihui Liu, Qian Li, Ming Luo, Rong Liang, Jiazhou Ye. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinomaJournal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1412-8
19
Pei-Chang Lee, Yee Chao, Ming-Huang Chen, Keng-Hsin Lan, Chieh-Ju Lee, I-Cheng Lee, San-Chi Chen, Ming-Chih Hou, Yi-Hsiang Huang. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular CarcinomaCancers 2020; 12(1): 182 doi: 10.3390/cancers12010182
20
Su Jong Yu, Tim F. Greten. Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular CarcinomaJournal of Liver Cancer 2020; 20(1): 1 doi: 10.17998/jlc.20.1.1
21
Akihisa Ueno, Yohei Masugi, Ken Yamazaki, Yutaka Kurebayashi, Hanako Tsujikawa, Kathryn Effendi, Hidenori Ojima, Michiie Sakamoto. Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinomaPathology International 2020; 70(3): 140 doi: 10.1111/pin.12895
22
Yoshito Tomimaru, Arihiro Aihara, Jack R. Wands, Costica Aloman, Miran Kim. A Novel Drug, CC-122, Inhibits Tumor Growth in Hepatocellular Carcinoma through Downregulation of an Oncogenic TCF-4 IsoformTranslational Oncology 2019; 12(10): 1345 doi: 10.1016/j.tranon.2019.07.002
23
Atsushi Ono, Hiroshi Aikata, Masami Yamauchi, Kenichiro Kodama, Waka Ohishi, Takeshi Kishi, Kazuki Ohya, Yuji Teraoka, Mitsutaka Osawa, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Tomokazu Kawaoka, Hiromi Abe-Chayama, Peiyi Zhang, Songyao Liu, Grace Naswa Makokha, Masataka Tsuge, Michio Imamura, C. Nelson Hayes, Kazuaki Chayama. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinibTherapeutic Advances in Medical Oncology 2020; 12: 175883592092205 doi: 10.1177/1758835920922051
24
Hansen Dang, Yee Hui Yeo, Satoshi Yasuda, Chung‐Feng Huang, Etsuko Iio, Charles Landis, Dae Won Jun, Masaru Enomoto, Eiichi Ogawa, Pei‐Chien Tsai, An Le, Matthew Liu, Mayumi Maeda, Brian Nguyen, Nathan Ramrakhiani, Linda Henry, Ramsey Cheung, Akihiro Tamori, Takashi Kumada, Yasuhito Tanaka, Ming‐Lung Yu, Hidenori Toyoda, Mindie H. Nguyen. Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and WestHepatology 2020; 71(6): 1910 doi: 10.1002/hep.30988
25
Hendrik Reynaert, Isabelle Colle. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the LiteratureInternational Journal of Molecular Sciences 2019; 20(19): 4811 doi: 10.3390/ijms20194811
26
Hong Zhao, Yujie Wang, Yufeng Liu, Xiaohua Hao, Hongshan Wei, Wen Xie. The Effect of Protein FAM172A on Proliferation in HepG2 Cells and Investigation of the Possible Molecular MechanismAnalytical Cellular Pathology 2019; 2019: 1 doi: 10.1155/2019/5901083